Journals / Ege Tıp Dergisi / 2022 / Cilt: 61 - Sayı: 2

Combinational effects of ponatinib and some Turkish endemic plant extracts on breast cancer cells

Ponatinib ve Türkiye’de yetişen bazı endemik bitki ekstrelerinin kombinasyonlarının meme kanseri hücreleri üzerindeki etkileri

Pages
232–243
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In light of the high anti-cancer effects identified, extracts of these Turkish endemic plants may represent a potential strategy in the treatment of breast cancer patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Breast cancer is the most common malignancy in women worldwide.
📊
Key Findings & Data:Therefore, there is a need to define new strategies that can overcome the deficiencies of existing treatments.
💡
Conclusion & Impact:In light of the high anti-cancer effects identified, extracts of these Turkish endemic plants may represent a potential strategy in the treatment of breast cancer patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Breast cancer is the most common malignancy in women worldwide. Therefore, there is a need to define new strategies that can overcome the deficiencies of existing treatments. In our study, we aimed to define new herbal combination therapies that can be used to target breast cancer cells. For this purpose, we investigated the cytotoxic, apoptotic, anti-proliferative and cell cycle regulatory effects of Centaurea calolepis (CCI), Origanum sipyleum (OSM) and Phlomis lycia (PLI) plant extracts in combination with ponatinib on MCF-7 cells. Materials and Methods: The cytotoxic effects of OSM, CCI, PLI and ponatinib on MCF-7 cells were measured in real time by xCELLigence. The median-effect equation was used for the analysis of combinations of ponatinib with CCI (p-CCI), OSM (p-OSM), PLI (p-PLI). Apoptosis, proliferation and cell cycle regulation were evaluated by flow cytometry. Results: The IC50 doses of CCI, OSM and PLI extracts in MCF-7 cells were calculated as 59.5, 57, 44.2 μg/ml at 48 hours and 51.6, 54.21, 42.52 μg/ml at 72 hours, respectively. Combination analyses revealed that p-CCI was additive, p-OSM and p-PLI showed a moderate synergistic effect at 48th hours. It was determined that apoptosis induced by ponatinib was significantly increased with the combinations of CCI and PLI. CCI and PLI treatments exhibited moderate anti-proliferative effects on MCF-7 cells, while OSM extract suppressed proliferation most significantly. Consistent with the proliferation results, the highest G0/G1 arrest was observed with OSM treatment. It was revealed that combined p-CCI and p-PLI treatments significantly increased the anti-proliferative effect of ponatinib and caused a higher level of G0/G1 accumulation. Conclusion: Combinations of ponatinib and CCI, OSM, PLI plant extracts exhibited anti-cancer activity in breast cancer with induction of apoptosis, suppression of proliferation and cell cycle arrest. In light of the high anti-cancer effects identified, extracts of these Turkish endemic plants may represent a potential strategy in the treatment of breast cancer patients.

Özet

Amaç: Meme kanseri, dünya genelinde kadınlarda en yaygın gözlenen malignansidir. Bu nedenle mevcut tedavilerin eksiklerini giderebilecek yeni stratejilerin tanımlanmasına ihtiyaç vardır. Çalışmamızda meme kanseri hücrelerinin hedeflenmesinde kullanılabilecek yeni bitkisel kombinasyon terapileri tanımlamayı hedefledik. Bu amaçla, Centaurea calolepis (CCİ), Origanum sipyleum (OSM) ve Phlomis lycia (PLİ) bitki ekstrelerinin ponatinib ile kombinasyonlarının MCF-7 hücreleri üzerindeki sitotoksik, apoptotik, anti-proliferatif ve hücre döngüsü üzerindeki etkileri araştırılmıştır. Gereç ve Yöntem: MCF-7 hücrelerinde OSM, CCİ, PLİ ve ponatinibin sitotoksik etkileri xCELLigence ile gerçek-zamanlı olarak ölçüldü. Ponatinib ile CCİ (p-CCİ), OSM (p-OSM), PLİ (p-PLİ) kombinasyonlarının analizleri için medyan-etki denklemini kullanıldı. Apoptoz, proliferasyon, hücre döngüsü düzenlenmesi akım sitometride değerlendirildi. Bulgular: MCF-7 hücrelerinde CCİ, OSM ve PLİ ekstrelerinin IC50 dozları sırasıyla 48. saatte 59,5, 57, 44,2 μg/ml ve 72. saatte 51,6, 54,21, 42,52 μg/ml olarak hesaplandı. Kombinasyon analizi sonuçlarına göre 48. saatte p-CCİ additif, p-OSM ve p-PLİ ılımlı sinerjistik etki sergilemekteydi. Ponatinib ile indüklenen apoptozun, CCİ ve PLİ kombinasyonlarıyla anlamlı düzeyde arttığı belirlendi. CCİ ve PLİ uygulamaları MCF-7 hücreleri üzerinde ılımlı düzeyde anti-proliferatif etki sergilerken, proliferasyonu en belirgin düzeyde OSM ekstresinin baskıladığı saptandı. Proliferasyon sonuçları ile uyumlu olarak, en yüksek G0/G1 tutulumu OSM uygulaması ile gözlendi. Kombine p-CCİ ve p-PLİ uygulamalarının ponatinibin anti-proliferatif etkisini anlamlı düzeyde arttırdıkları ve daha yüksek düzeyde G0/G1 birikimine neden oldukları ortaya koyuldu. Sonuç: Ponatinib ile CCİ, OSM, PLİ bitki ekstrelerinin kombinasyonları apoptozu indükleyerek, proliferasyonu baskılayarak ve hücre döngüsünün durdurarak meme kanserinde anti-kanser aktivitesi sergiledi. Belirlenen yüksek anti-kanser etkilerinin ışığında, Türkiye’de yetişen bu endemik bitki ekstreleri meme kanseri tedavisinde potansiyel strateji temsil edebilir.

🔖

Cite This Article

KAYABAŞI, Ç., AVCI, Ç. B., BALCIOKCANOĞLU, T., DURMUŞKAYA, C., KAYALAR, H., ÖZBİLGİN, A., GÜNDÜZ, C., SÜSLÜER, S. Y., YELKEN, B. Ö., KURT, C. Ç., BAĞCA, B. G. (2022). Combinational effects of ponatinib and some Turkish endemic plant extracts on breast cancer cells. Ege Tıp Dergisi, Cilt: 61 - Sayı: 2, 232–243. https://ajindex.com/articles/495996

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Arya GC, Kaur K, Jaitak V. Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. Eur J Med Chem 2021; 221: 113511
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (1): 7-34
  3. Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem 2015; 6 (3): 231-9
  4. Eric I, Petek Eric A, Kristek J, Koprivcic I, Babic M. Breast Cancer in Young Women: Pathologic and Immunohistochemical Features. Acta Clin Croat 2018; 57 (3): 497-502
  5. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, ve ark. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010; 53 (12): 4701-19
  6. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, ve ark. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77 (1): 1-11
  7. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, ve ark. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16 (5): 401-12
  8. Dickson C, Spencer-Dene B, Dillon C, Fantl V. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2000; 2 (3): 191-6
  9. Jitariu AA, Raica M, Cimpean AM, Suciu SC. The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast. Crit Rev Oncol Hematol 2018; 131: 46-52
  10. Singh DD, Yadav DK. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedicines 2021; 9 (8): 876 11. Musumeci F, Greco C, Grossi G, Molinari A, Schenone S. Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia. Cancers (Basel) 2018; 10 (11): 430 12. Shao W, Li S, Li L, Lin K, Liu X, Wang H, ve ark. Chemical genomics reveals inhibitin of breast cancer lung metastasis by Ponatinib via c-Jun. Protein Cell 2019; 10 (3): 161-77
  11. Kim S, You D, Jeong Y, Yoon SY, Kim SA, Lee JE. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin e